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Abstract 
Review on EEF1A1, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: CCS-3, CCS3, EF1A, EEF1A, EEF-
1, GRAF-1EF, LENG7, PTI1 
HGNC (Hugo): EEF1A1 
Location: 6q13 
Local order 
Distal to LOC100129409, proximal to SLC17A5. 
DNA/RNA 
Description 
8 exons, 7 introns (1st intron within 5'UTR), plus a 
rare optional exon within first intron as found in 
several ESTs (e.g. emb-CR981691.1, dbj-
DC388133.1, dbj-DC406334.1). 
Presumably a second promoter, about 800 nt 
upstream of the most common transcription start,  
provides an alternative first exon about 320 nt long, 
as deduced from some ESTs at NCBI (e.g. dbj-
DC316623.1, gb-BU173251.1, dbj-DC358918.1). 
Introns number 2, 3, 4, 6 are phase 0 (between 
codons), introns number 5, 7 are phase 1 (between 
1st and 2nd base of codon). 
A validated C-G non-synonimous polymorphism 
has been reported at 1st position of codon 382 (Arg-
Gly), plus a few single-hit non-synonimous and 
some synonymous within CDS. Several others 
within 3'UTR and introns (SNP source). 
Transcription 
The main processed mRNA encompasses exons 1, 
2, 3, 4, 5, 6, 7, 8, this last can be in short or long 
form. In a few cases also exon 1' is retained.  
In a few cases exons 1 (and 1') are substituted by 
the alternative exon from a putative upstream minor 
promoter, as described above.  
Moreover, a quite high number of processed 
transcripts that, after exons 1 and 2, retain intron 2, 
which introduces a stop codon 22 residues 
downstream of exon 2 are found (see for instance 
some of the many ESTs: dbj-DC389722.1, dbj-
DC341899.1, dbj-DC414491.1). 
 
Box = exon (blue = 5'UTR, yellow = CDS, light blue = rare optional exon, red = 3'UTR, light red = extended 3'UTR to a 
downstream polyA signal); line = intron. 
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Upper boxes, alternating colours: exons (coding part only); lower boxes: protein domains. 
 
 
Pseudogene 
About 20 complete or approximately complete 
intronless pseudogenes, likely generated by 
retrotransposition, a few of them exempt from 
frameshifs and with only a few missenses, are 
present throughout the genome.  
Two of them harbour a few hundreds nt long insert 
each, not related to introns of the expressed gene. 
All of them show a higher homology to EEF1A1 
than to EEF1A2.  
Most of the pseudogenes find an orthologous 
counterpart within the chimpanzee genome. 
EEF1AL3 (9q34) (highly homologous); EEF1AL4 
(7p15.3) (highly homologous but with 1 
frameshift); EEF1AL5-LOC390924 (19q13.12) 
(contains a 502 nt insert); EEF1AL6 (3q27.1); 
EEF1AL7 (4q24); EEF1AL8-LOC100132804 
(7q35); EEF1AL9 (1p21.3); EEF1AL10-
LOC644604 (2q12); EEF1AL11 (5p15.1) (rather 
highly homologous); EEF1AL12-LOC647167 
(1q31.3); EEF1AL13-LOC100130211 (Xq21.2) 
(lacking about 300 initial codifying nt); 
LOC124199 (16p12.1) (contains a 307 nt insert); 
LOC387845 (12p12.3); LOC389223 (4q28.3); 
LOC401717 (12q12); LOC442709 (7q21.13) 
(harbours a 21 nt deletion); LOC645693 (15q21.2); 
LOC645715 (3p22.1); LOC646612 (3q22.3) 
(lacking about 120 initial codifying nt); 
LOC728672 (12p12.3); LOC100128082 (5p12). 
Protein 
Note 
The major form of the protein is 462 residues long, 
composed by three domains, as shown by the 
diagram, that relates also the protein domains 
(lower bar) with mRNA coding exons (upper bar). 
Description 
462 residues, theoretical MW: 50140.8 Da, 
theoretical isoelectric point: 9.7. eEF1A1 is one of 
the alpha subunit forms of the elongation factor 1 
complex, that interacts with aminoacylated tRNA 
and delivers it to the A site of the ribosome during 
the elongation phase of protein synthesis.  
The other form is eEF1A2, encoded by a different 
gene, EEF1A2, located in chromosome 20. 
Expression 
EEF1A1 is constitutively expressed in all tissues, 
with the exception of adult brain, heart and skeletal 
muscle, where EEF1A2 expression is found. 
Localisation 
Mostly cytoplasmic, but also nuclear. 
Function 
Canonical function: aa-tRNA delivery to ribosome 
in mRNA translation 
The eukaryotic elongation factor 1A (eEF1A1, 
formerly EF-1alpha or eEF1A) protein belongs to 
the G-protein superfamily, is one of most 
abundantly expressed protein in mammalian cells 
and participates to mRNA translation. It carries 
aminoacyl-tRNA (aa-tRNA) to the A site of the 
ribosome as a ternary complex eEF1A1-GTP-aa-
tRNA. In mammalian, it is ubiquitously expressed 
with exception of skeletal muscle, heart and brain 
where during terminal differentiation eEF1A2 is 
produced (Knudsen et al., 1993). 
Moonlighting functions: cytoskeletal remodelling, 
protein folding and degradation, cell signalling 
modulation, control of cell growth, apoptosis and 
cell cycle 
1) eEF1A1 and cytoskeletal remodelling. The 
most relevant non canonical function of eEF1A1 is 
the modulation of cytoskeleton organization. 
eEF1A has activity on microtubule severing and 
bundling. It has a specific site to bind actin that is 
different from that for the binding of aa-tRNA 
(Gross and Kinzy, 2005). eEF1A binding to F-actin 
is modulated by Rho/Rho-kinase pathway. 
Phosphorylation by Rho kinase decreases the 
binding of eEF1A1 to F-actin and F-actin bundling. 
Myosin phosphatase acts in antagonist fashion on 
eEF1A1 to modulate actin cytoskeletal organization 
(Izawa et al., 2000). 
2) eEF1A1 and protein degradation and folding. 
eEF1A controls translational fidelity by binding to 
incorrectly folded proteins but not to correctly 
folded ones. The incorrectly folded proteins are 
then directed to degradation pathway (Hotokezaka 
et al., 2002). eEF1A plays a role in recognition and 
degradation of co-translationally damaged and 
ubiquitylated proteins promoting their translocation  
 
 
EEF1A1 (eukaryotic translation elongation factor 1 alpha 1) Scaggiante B, Bosutti A 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(4) 258 
to proteasome through interaction with proteasome 
subunit Rpt1 (Chuang and Madura, 2005). eEF1A 
exhibits chaperone-like activity by promoting 
renaturation of enzymes such as aminoacyl-tRNA 
synthetases, likely contributing to maintain the 
efficiency of translational machinery (Lukash et al., 
2004). 
eEF1A1 takes part in the aggregosome formation 
upon proteosome failure by activating heat shock 
response to degrade uncorrected folded proteins, to 
favor clearance of protein aggregates and to protect 
cell from proteotoxicity by favoring autophagy 
(Meriin et al., 2012). 
3) eEF1A1 and control of cell cycle, growth and 
death. eEF1A as ribonucleoprotein complex, 
containing a non-coding RNA, binds to and 
mediates activation of heat-shock transcription 
factor 1 (HSF1) to protect the cell from heat-shock 
(Shamovsky et al., 2006). Induction of the non-
constitutive eEF1A1 expression in cardiomyocytes 
as response to lipotoxic ER-stress promotes cell 
death likely by activation of eEF1A1-dependent 
cytoskeletal modifications triggering apoptosis 
(Borradaile et al., 2006). eEF1A1 interacts with the 
HDM2 gene product at a binding site for eEF1A1 
overlaps with that for p53. In normal cells eEF1A1 
could promote cell apoptosis by preventing p53 
sequestration by HDM2 (Frum et al., 2007). Likely 
both eEF1A1 and eEF1A2 interacts with the zinc 
finger protein ZPR1 in response to mitogenic 
stimuli, redistributing eEF1A1/2 and ZPR1 in the 
nucleus. This interaction is essential for normal cell 
proliferation and growth. Thus the interaction 
eEF1A1/2-ZPR1 is required for normal cell cycle 
progression (Mishra et al., 2007). eEF1A1 is an 
interactor of Bood POZ containing gene type 2 
(BPOZ-2) that promotes eEF1A1 ubiquitylation 
and degradation via 26S proteasome. BPOZ-2 
inhibits GTP binding to eEF1A1 thus preventing 
translation. BOPZ-2 is transcriptionally activated 
by phosphate and tensin homologue deleted on 
chromosome 10 (PTEN). It has been suggested that 
PTEN exerts growth inhibition effects in cells not 
only by antagonizing PI3K-Akt signalling pathway, 
but also inducing BPOZ-2 expression to degrade 
eEF1A1. In this manner, in normal cells, the 
transition from growing to resting phases is 
mediated by BPOZ-2/eEF1A1 interaction, thus 
leading to prevention of translation and induction of 
eEF1A1 degradation by 26S proteasome pathway 
(Koiwai et al., 2008). eEF1A1 is implicated in a 
novel cell cycle check-point to prevent tetraploidy 
in binucleated cells. In tetraploids, cell death, 
preventing aneuploidy malignancies, is mainly 
controlled in a caspase-independent manner by the 
down-regulation of eEF1A1 levels. eEF1A1 mRNA 
accumulates in specialized P bodies to reduce the 
expression of the proteins. The prominent signal in 
the eEF1A1 mRNA for its translational repression 
and degradation is in the 5'-UTR. Exogenous 
expression of eEF1A1 inhibits cell death in 
tetraploids. Notably, exogenous expression of 
eEF1A2 whose mRNA 5'-UTR differs from that of 
eEF1A1 inhibits cell death in tetraploids, thus 
suggesting another mechanism by which eEF1A2 
could promote tumour development (Kobayashi 
and Yonehara, 2009). 
Cell adhesion to the extracellular matrix is an 
essential biological event for cell survival and 
proliferation in multicellular organisms. Disruption 
of integrin-mediated cell adhesion leads to a 
specific type of apoptosis known as anoikis in most 
non-transformed cells. Recent evidences show 
eEF1A to act as a membrane receptor for the 
cryptic anti-adhesive site of fibronectin, which 
contributes to cell regulation, including anoikis, 
through negative modulation of cell anchorage. 
Possibly, the membrane-resident eEF1A may 
interact with beta1-integrins inactivating their 
functions in cell adhesion (Itagaki et al., 2012). 
Down-regulation of eEF1A1 seems to be specific to 
senescence. Changes in eEF1A expression levels 
has been proposed also as promising marker for the 
detection of cellular cancer senescence induced by a 
variety of treatments, such as ionizing radiation 
(Byun et al., 2009). 
4) eEF1A1 and cell signalling modulation. 
Besides eEF1A2, in adult mouse neurons eEF1A1 
is expressed too and it is able to regulate the recycle 
of M4 muscarinic acetylcholine receptors 
(mAChR). Thus, eEF1A1 plays a role in locomotor 
activity of neurons (McClatchy et al., 2006). 
eEF1A1 modulates the activities of sphingosine 
kinases (SK1 and SK2). Phosphorylated and non-
phosphorylated eEF1A1 forms interact with 
phosphorylated and non phosphorylated SK1 and 
SK2 and this results in an increased enzymatic 
activity of both SK1 and SK2. In this respect, 
overexpression of eEF1A1 in quiescent cells has 
been suggested to play a role in oncogenesis by 
increasing SK1 and SK2 activities (Leclercq et al., 
2008). eEF1A1 is involved in the regulation of 
vascular function mediated by TNF-alpha. eEF1A1 
binds to 3'-UTR of the endothelial nitric oxide 
synthase (eNOS) to regulate post-translational 
eNOS mRNA stability. In the human endothelial 
cell line HUVEC, TNF-alpha-mediated eNOS 
mRNA destabilization involves eEF1A1 to reduce 
eNOS mRNA levels (Yan et al., 2008). 
The different phosphorylation pattern between 
eEF1A1 and eEF1A2 especially at tyrosine levels 
has been suggested to determine structural 
differences of the two isoforms. In particular, 
eEF1A1 behaves a more extended structure with 
respect to the more compact one of eEF1A2 
(Negrutskii et al., 2012). 
Phosphorylation of eEF1A1 on serine (S21) and 
threonine (T88) residues by Raf kinases regulates 
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eEF1A1 stability. The in vitro phosphorylation of 
S21 residue in both eEF1A1 and eEF1A2 proteins 
by Raf kinases is suggested to cause conformational 
change in the proteins thus impairing GDP/GTP 
exchange factor interaction and switching the 
proteins from the protein biosynthesis to the non-
canonical functions. Although S21 phosphorylation 
has not been found in vivo, in eEF1A constructs 
transfected COS 7 cells, S21 and T88 mutants 
showed that these sites affect proteins stability. 
Interestingly, eEF1A1 has a unique phosphorylation 
site on threonine and tyrosine (T88 and Y86, 
respectively). Furthermore, phosphorylation 
deficiency at S21 decreased protein half-time and 
increased cell apoptosis. Thus modulation of 
eEF1A1 phosphorylation at S21 is proposed to be 
implicated in cell proliferation and apoptosis 
regulation (Sanges et al., 2012). 
eEF1A1 is involved also in cytokine cell signaling. 
In particular, TGFβ1 signalling regulates cell 
proliferation by acting on TβR-I that 
phosphorylates eEF1A1 at the Ser300 located in the 
domain for aa-tRNA binding. This impairs protein 
synthesis and leads to a lower proliferation rate of 
the cells. Worth of note that this effect is exerted 
directly on mRNA translation without 
transcriptional activation (Lin and Souchelnytskyi, 
2011). 
eEF1A1 is also a component of the 
ribonucleoprotein complex in the transcript-
selective translational regulatory pathway mediated 
by the TGFβ-activated translational element (BAT). 
BAT is a 33-nt structural RNA element in the 3'-
UTR of disabled-2 (Dab2) and interleukin like 
EMT inducer (ILEI). Dab2 and ILEI are two 
mRNAs mediating epithelial to mesenchymal 
transition. TGFβ-induced EMT is essential during 
embryonic development. In BAT element, eEF1A1 
interacts with hnRNP E1 to inhibit translation, 
blocking the progression of the 80S ribosome by 
preventing eEF1A1 release from A site following 
hydrolysis of GTP. In this way the translation is 
inhibited by the stall at the eEF1A1-dependent 
elongation stage. Thus eEF1A1 and hnRNP E1 play 
a fundamental role in EMT by repressing specific 
gene expression (Hussey et al., 2011). 
In U343 glioma cells eEF1A1 was found to be the 
target of heteroalkylketones, compounds that lower 
interleukin-6 (IL-6) activity in chronic 
inflammation. By this finding, eEF1A1 was shown 
to play a critical role in chronic inflammation 
sustaining IL-6 activity by forming a complex with 
STAT3 and PKCδ that promotes phosphorylation 
of STAT3 at serine 727. This in turn triggers NF-
kB/STAT3 interaction enhancing IL-6 expression 
(Schulz et al., 2014). 
In neurons, both eEF1A1 and eEF1A2 isoforms 
have been found to bind to gephyrin protein, a 
scaffold protein which is thought to anchor 
GABAA-receptors to the cytoskeleton. 
Overexpression of both eEF1A proteins in cultured 
hippocampal neurons has been also associated with 
a significant increase in number, size and density of 
postsynaptic gephyrin clusters.  
Therefore, eEF1A proteins involvement in 
modulating receptor cluster formation and/or 
maintenance in neurons and in the morphology of 
postsynaptic membrane specializations at inhibitory 
synapses, is strongly emphasize (Becker et al., 
2013). 
Homology 
Highly homologous over the entire length to: 
- EEF1A2 (92% identities). 
Moderately homologous over all three domains, 
higher for the first one, to: 
- HBS1L, a member of the GTP-binding protein 
family expressed in erythroid progenitor cells (39% 
identities), 
- GSPT1, a GTP-binding protein involved in G1 to 
S phase transition (38% identities), 
- GSPT2, a GTP-binding protein involved in G1 to 
S phase transition (37% identities), 
- TUFM, Tu translation elongation factor, 
mitochondrial (31% identities). 
Implicated in 
Head and neck cancers 
Note 
eEF1A1 overexpression is observed in cisplatin-
resistant human head and neck cancer cell lines 
(Johnsson et al., 2000). 
Breast cancer 
Note 
EEF1A1 was found to be up-regulated in invasive 
breast cancer cells derived from snap-frozen 
adenocarcinoma samples suggesting a role in 
mediating invasive activity of cancer cells (Zhu et 
al., 2003).  
Treatment of the breast human cancer cell line 
MCF-7 with the histone deacetylase inhibitor 
sodium butyrate decreases significantly in a dose-
dependent manner the eEF1A1 transcription levels. 
Thus, overexpression of eEF1A1 contributes to 
breast cancer survival (Gonçalves et al., 2005).  
An analysis of human breast cancer cases revealed 
a decrease of eEF1A1 phosphorylation at Ser300 in 
malignant tumor cells as compared to epithelial 
cells in noncancerous tissues (Lin et al., 2010). 
Tongue squamous cell carcinoma 
Note 
A suggestive down-regulation of EEF1A1 
expression has been observed in human tongue 
squamous cell carcinoma with positive 
lymphonodes and extracapsular spread. Thus 
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EEF1A1 down-regulation might be involved in the 
tumour cell progression toward the metastasis 
(Zhou et al., 2006). 
Hepatocarcinoma 
Note 
eEF1A1 overexpression in human hepatocarcinoma 
cell lines correlates with an increase of proliferation 
rate and with the ability to escape apoptosis under 
suboptimal growth conditions.  
In particular eEF1A1 overexpression is higher in 
the more aggressive phenotype cell line JHH6 with 
respect to the more differentiated HepG2 and HuH7 
cells (Grassi et al., 2007).  
eEF1A1 regulates the half-life of osteopontin 
(OPN) mRNA. eEF1A1 is a trans-acting factor that 
binds to 5'-UTR of OPN.  
This has strong implications in the invasive process 
as demonstrated in hepatocellular carcinoma cells, 
OPN being the major secreted phosphoprotein 
which is overexpressed by tumour cells in advanced 
metastatic cancer.  
The higher expression of OPN in invasive cancer 
cells is due to the different localization of eEF1A1: 
in non-invasive Hep3B cells it is mainly bound to G 
actin whereas in invasive HepG2 type eEF1A1 and 
G actin association is minimal.  
Thus eEF1A1 is an indirect regulator of OPN by 
affecting the OPN mRNA stability through the 
interaction with G actin. Only F actin-bound 
eEF1A1 cannot interact with 5'-UTR of OPN 
(Zhang et al., 2009).  
Recently, it has been proposed a model in which 
eEF1A1 is a binder of the ubiquitin-like protein 
HLA-F adjacent transcript 10 (FAT10), a small 
ubiquitin-like modifier which functions include 
modulation of cytokine responses, apoptosis, 
mitosis, and tumorigenesis, to carry out, in part, 
functions in regulating tumorigenesis in human 
Hep3B hepatocellular carcinoma cell line. Thus 
eEF1A1 can play a role in this type of cancer by its 
mutual regulation with FAT10 (Yu et al., 2012). 
Trichloroethylene (TCE) is a major pollutant found 
in many occupational and environmental sites. TCE 
exposure is known to promote cancerogenesis. In 
normal hepatic L-02 cell line, TCE exposure up-
regulates the SET protein, a nuclear protein playing 
a role in regulation of gene expression and 
phosphorylation cell pathways. An isoform of SET 
(SET/TAF-Iα) was found to interact both with 
eEF1A1 and eEF1A2 proteins. The hepatotoxicity 
of L-02 cells resulted in an enhanced interaction of 
SET with eEF1A2, a set redistribution from nucleus 
to cytoplasm and eEF1A1 translocation from 
cytoplasm to the nucleus. The SET/TAF-Iα/eEF1As 
interaction is suggested to sustain hepatotoxicity 
and carcinogenesis (Hong et al., 2012). 
Testicular germ tumours 
Note 
eEF1A1, as well as eEF1A2, is an interactor of the 
human testis-specific Y-encoded (TSPY) gene. It 
has been demonstrated that the binding to TSPY 
leads to a redistribution of the TSPY-eEF1A1/2 
complex in the cell with a nuclear co-localization. 
A role of the TSPY-eEF1A1/2 complex has been 
suggested in promoting neoplastic transformation 
and in sustaining cancer cell growth in human 
testicular germ tumours, prostate cancer, as well as 
in other somatic cancers (Kido and Lau, 2008). 
Cervical cancer 
Note 
A variant form of eEF1A1 named cervical cancer 
suppressor 3 (CCS-3) lacking the 101 aminoacids at 
the N-terminal region, has been identified as 
tumour suppressor that is present in non-
transformed human cell lines. Its ectopical 
expression in a cervical tumour cell line leads to 
cell growth inhibition and apoptosis. CCS-3 seems 
to act as a co-transcriptional repressor by 
interacting with the transcriptional regulator PLZF 
(Rho et al., 2006). 
The mRNA of CCS-3 (GenBank Accession 
AF322220) appears to be a fusion product joining 
the reverse of the end portion of the 3' UTR of 
another product (NM_005763, from gene AASS) 
with most of the normal sequence of EEF1A1 
mRNA. 
CCS-3 seems to enhance the transcriptional 
repression of the p21CIP1 gene (hereafter referred 
to as p21) by FBI-1, a member of the POK (POZ 
and Kruppel) family of transcription factors, 
playing a role in differentiation, oncogenesis, and 
adipogenesis. The POZ-domain of FBI-1 interacts 
with the co-repressors, SMRT and BCoR. It has 
been found that FBI-1 directly interacts with 
eEF1A and CCS-3 via the zinc finger and POZ-
domain and that FBI-1 co-localizes with either 
eEF1A or CCS-3 at the nuclear periplasm. CCS-3 
also interacts with the co-repressors independently. 
This evidence suggests that CCS-3 may be 
important in cell differentiation, tumorigenesis, and 
oncogenesis by interacting with the proto-oncogene 
FBI-1 and with transcriptional co-repressors (Choi 
et al., 2009). 
Prostate cancer 
Note 
Overexpression of eEF1A proteins has been 
reported to have a role in prostate cancer (PCa) and 
may affect multiple processes involved in tumor 
progression. eEF1A1 is up-regulated in human 
prostate cancer as resulted by iTRAQ-based 
analysis of serum samples derived from patients  
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with prostatic disease and by 
immunohistochemistry of prostate cancer tissues 
with localized metastasis. Bone metastases 
represent the major risk in patients with prostate 
cancer progression. eEF1A1 up-regulation seems to 
be linked to the osteoblastic nature of the metastasis 
and high levels of eEF1A1 in patients' sera could 
mark metastatic progression. At histological level, 
the median immunostaining intensity of eEF1A1 
was significantly higher in osteoblasts in close 
proximity to metastatic tumour cells compared with 
osteoblasts in control bone (Rehman et al., 2012).  
In vitro studies shown differential expression level 
of eEF1A1 in four PCa cell lines (22RV1, LNCaP, 
DU-145, and PC-3), suggesting a possible role of 
the protein in the pathogenesis of PCa. In DU-145, 
a high-grade metastatic PCa cell line, eEF1A1 plays 
an essential role in cellular properties associated 
with tumor progression, specifically in cell 
proliferation, invasion, and migration. In fact, 
eEF1A1 suppression inhibits DU-145 cell 
migration and invasion (Zhu et al., 2009). 
Dissecting the role of eEF1A1 with respect to 
eEF1A2 in human cancer cell lines, the quote of 
eEF1A1 associated to the cytoskeleton is 
significantly up-regulated in cancer cells referring 
to the non-tumorigenic ones. However, eEF1A2 
seems to better mark the prostate cancer onset and 
progression either in cell lines that or in human 
prostate tissue samples (Scaggiante et al., 2012). 
Prostate adenocarcinoma, colon 
adenocarcinoma, pancreatic cancer 
and gastric cancer 
Note 
A variant form of eEF1A1 lacking 67 aminoacids at 
the N-terminal region has been proposed to 
promote cell transformation and to sustain tumour 
cells viability. It has been named prostate inducing 
gene-1 (PTI-1), also known as elongation factor 
1A-like 14. Initially identified by differential RNA 
display screening of cDNA expression library in the 
human prostate cancer cell line LNCaP, it has been 
proposed to act as a dominant oncogene in human 
prostatic adenocarcinoma. Its mRNA contains a 5'-
UTR of 630 bp that is highly homologous to part of 
the 23S rRNA of Mycoplasma sp. fused to most of 
the CDS of EEF1A1, resulting in the substitution of 
its first 67 N-terminal residues with Met-Gln-Ser 
(Sun et al., 1997; Mansilla et al., 2005). Ectopically 
forced expression of PTI-1 in a mouse cell line 
induces tumours in nude mice and antisense PTI-1 
molecule can reverse malignant phenotype of the 
transformed cells (Su et al., 1998). Silencing of 
PTI-1 by specific RNAi not affecting eEF1A1 
expression, in a human prostate cancer cell line 
leads to a reduction of cellular growth, to the block 
of cell cycle in G1 phase and to the promotion of 
apoptosis (Yu et al., 2006). It has been 
hypothesized that PTI-1 could promote cell 
transformation by causing translational infidelity 
being in competition with eEF1A1 (Gopalkrishnan 
et al., 1999). PTI-1 mRNA is detected only in 
human cancer cells upon Mycoplasma infection. It 
remains under investigation whether PTI-1 can play 
a role in the natural history of human prostatic 
adenocarcinoma upon Mycoplasma infection. The 
origin of the chimeric transcript of PTI-1 remains to 
be ascertained (Scaggiante et al., 2008). PTI-1 
mRNA has been detected in multidrug-resistance 
colon cancer cell line LoVoDX (Bertram et al., 
1998). By using the detection of a unique PTI-1 
region between the 5'UTR and the CDS, PTI-1 
mRNA has been found in the human pancreatic 
cancer cell line AsPC-1, in the human gastric 
cancer TMK-1 cells, and in the hepatoma 
Alexander cells, but not in several other pancreatic, 
gastric and hepatoma human cancer cell lines. 
Interestingly, in AsPC-1 cells the down-regulation 
of K-ras mRNA by antisense leads to a reduction of 
PTI-1 level. PTI-1 mRNA was detected in three of 
five surgical human specimens of pancreatic cancer 
(Ohnami et al., 1999).  
A study conducted with PTI-1 plasmid constructs 
either in vitro or in transfected NIH3T3 cells, 
revealed that the oncogenic potential of PTI-1 is 
related to a transcript product variant derived from 
the second AUG in frame codon (ORF 2). This 
transcript of this construct (PTI-1-FL-∆ATG) leads 
to a 39 kDa protein and the transfected cells gave 
multiple foci in growth assay. Interestingly cells 
expressing PTI-1-FL-∆ATG construct gave tumors 
when injected in NCr nude mice. The oncogenic 
potential of the 39 kDa PTI-1 protein resulted 
dependent on the nuclear localization of the protein 
in the cells which in turn was strictly related to the 
UTRs-containing transcripts (more likely the 
5'UTR). It is speculated that the nuclear localization 
of PTI-1 is essential to exert its oncogenic potential, 
may be by interfering with the nuclear eEF1A1 
functions modulating cellular proliferation (Dahl et 
al., 2014). 
Cutaneous T-cell lymphoma 
Note 
In human sera derived from cutaneous T-cell 
lymphoma (CTCL) patients one of the new tumour 
antigens was a truncated version of eEF1A1 lacking 
77 aminoacids at N-terminal. 
Leukemia 
Note 
In the promyelocytic human leukemia cells the 
differentiation agent all-trans-retinoic acid (ATRA) 
induces down-regulation of eEF1A1 thus 
suggesting a role in contributing to cancer survival 
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in haematopoietic malignancies (Harris et al., 
2004). 
An isoform of eEF1A1 with a more basic 
isoelectric point was identified in human 
haematopoietic cancer cell lines but not in normal 
lymphocytes raising the possibility that post-
translation modifications of eEF1A1 could be 
involved in cancer development and progression of 
haematopoietic tumours (Dapas et al., 2003). 
The selective inhibition of eEF1A1 isoform by 
specific GT aptameric oligonucleotides, carried by 
the ethoxylated polyethylenimine, a weak basic 
polycation, has been demonstrated to exert specific 
cytotoxic effect and dose-dependent cell growth 
inhibition on lymphoblastic cancer cells 
(Scaggiante et al., 2005). 
Moreover the more basic isoform expression can be 
induced by phorbol ester in normal human 
lymphocytes and inhibited in T-lymphoblastic 
CCRF-CEM cancer cell line upon differentiation 
stimuli.  
Thus, this suggests a role of the more basic isoform 
in leukemia onset (Scaggiante et al., 2013). 
In human acute T lymphocytic leukemia Jurkat cell 
line, eEF1A1 expression sustained cell proliferation 
inhibiting apoptosis by up-regulating PI3K/Akt/NF-
kB and PI3K/Akt/mTOR signaling pathway (Huang 
et al., 2013). 
Chemioresistance of tumors 
Note 
eEF1A1 is a novel interactive partners of p73 that 
in vivo forms complexes with all three p53 family 
proteins (i.e. p53, p63 and p73).  
In particular, eEF1A1 negatively modulates wild 
type p53 and TAp73 tumor suppressors in many 
human cancer cell lines (HeLa cervical carcinoma, 
SaOS-2 and U2OS osteosarcoma, HEK293A 
embryonic kidney, A549 lung carcinoma and 
HCT116 colon carcinoma).  
The ectopic expression of eEF1A1 inhibits p53 and 
p73-induced apoptosis. Interestingly, over-
expression of eEF1A1, but not eEF1A2, inhibits 
chemotherapy-induced apoptosis in cancer cells. In 
cancer cells following chemotherapy, eEF1A1 
negatively modulates p53 and p73 stability thus 
sustaining pro-survival activity.  
The silencing of eEF1A1 sensitizes the cancer cells 
to chemotherapics (Blanch et al., 2013). 
Felty's syndrome 
Note 
Characterized by rheumatoid arthritis, 
splenomegaly and neutropenia. eEF1A1 is found as 
autoantigen (Ditzel et al., 2000). 
 
Skeletal muscle trauma and motor 
neuron degeneration 
Note 
Several studies have indicated that muscle 
catabolism is associated with an increased 
expression and activity of critical components of 
proteolytic and apoptotic systems. In human tissues, 
eEF1A1 is ubiquitously expressed, with the 
exception of skeletal muscle, heart, and brain, 
where it progressively declines at the early phases 
of development. In adult muscle, eEF1A2 takes 
over the eEF1A1-specific function for protein 
synthesis. In aging rats, muscle eEF1A1 
transcription increases, reverting the 
eEF1A1/eEF1A2 ratio. In contrast to the rat model, 
in humans, there is no increase of eEF1A1 
messenger RNA (mRNA)/protein in the late phases 
of life. In hypercatabolic traumatized patients 
eEF1A1 mRNA level significantly rose in skeletal 
muscle as the result of injury. eEF1A1 expression 
correlated with overexpression of p66(ShcA) 
(Bosutti et al., 2007). 
An overexpression of genes associated with the 
regeneration of axons, including eEF1A1, gamma-
actin, PMP22, SPARC/osteonectin, CD9, and 
CD44 has been identified in nerve biopsies from a 
patient presenting an axonal form of Charcot-
Marie-Tooth disease (CMT), one of the most 
common inherited peripheral neuropathies which is 
characterized by repeated rounds of nerve 
degeneration and regeneration (Cavalcanti et al., 
2009).  
Additionally, a novel eEF1A binding protein, 
immunoglobulin-like and fibronectin type III 
domain containing 1 (IGFN1), has been discovered 
in a yeast two-hybrid screening of a human skeletal 
muscle cDNA library. IGFN1 is specifically 
expressed in skeletal muscle and is substantially up-
regulated during muscle denervation. It presents 
immunoglobulin I and fibronectin III sets of 
domains characteristic of sarcomeric proteins and 
shows sequence and structural homology to myosin 
binding protein-C fast and slow-type skeletal 
muscle isoforms. Increased expression of IGFN1 
has been proposed to down-regulate protein 
synthesis via interaction with eEF1A during 
denervation (Mansilla et al., 2008). Noteworthy, the 
reciprocal pattern of expression of eEF1A1 and 
eEF1A2 in muscle fits with the timing of onset of 
the phenotype of wasted mice: eEF1A1 declines 
after birth until and it is undetectable by 3 weeks; 
on the contrary eEF1A2 expression increases over 
this time. No other gene is present in the wasted 
deletion, and transgenic studies have shown that the  
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phenotype is due to loss of eEF1A2 translation 
activity in muscle (Doig et al., 2013; Abbott et al., 
2009).  
In neuronal cells, an eEF1A1 interaction with the 
yeast two-hybrid protein K (HYPK), highlights the 
involvement of HYPK in the regulation of cell 
growth, cell cycle, unfolded protein response and 
cell death. Cellular responses were significantly 
enhanced with HYPK-interacting partners and 
eEF1A1 - protein interaction (Choudhury et al., 
2012).  
Gbx2 gene, encoding a DNA-binding transcription 
factor, is required to the development of the anterior 
hindbrain, spinal cord, inner ear, heart, and neural 
crest cells, during embriogenesis. EEF1A1 has been 
reviled as one of the top candidate gene vital to 
Gbx2 action in nervous system development. 
GBX2 activates transcriptional activity through the 
promoter of EEF1A1, suggesting that GBX2 could 
also regulate gene expression indirectly via EEF1A 
(Roeseler et al., 2012). 
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